A potential role for activated HER-2 in prostate cancer

[1] Agus DB, 1999, CANCER RES, V59, P4761

[2] Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) : 1869 - 1876

[3] THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J]. NATURE, 1986, 319 (6050) : 226 - 230

[4] CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303

[5] Carter P, 2000, Breast Dis, V11, P103

[6] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446

[7] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648

[8] A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J]. NATURE MEDICINE, 1999, 5 (03) : 280 - 285

[9] Growth factors in steroid-responsive prostatic tumor cells [J]. STEROIDS, 1996, 61 (04) : 222 - 225

[10] DOWN-MODULATION OF AN ONCOGENE PROTEIN PRODUCT AND REVERSION OF THE TRANSFORMED PHENOTYPE BY MONOCLONAL-ANTIBODIES [J]. CELL, 1985, 41 (03) : 695 - 706

[1] Agus DB, 1999, CANCER RES, V59, P4761

[2] Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) : 1869 - 1876

[3] THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J]. NATURE, 1986, 319 (6050) : 226 - 230

[4] CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303

[5] Carter P, 2000, Breast Dis, V11, P103

[6] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446

[7] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648

[8] A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J]. NATURE MEDICINE, 1999, 5 (03) : 280 - 285

[9] Growth factors in steroid-responsive prostatic tumor cells [J]. STEROIDS, 1996, 61 (04) : 222 - 225

[10] DOWN-MODULATION OF AN ONCOGENE PROTEIN PRODUCT AND REVERSION OF THE TRANSFORMED PHENOTYPE BY MONOCLONAL-ANTIBODIES [J]. CELL, 1985, 41 (03) : 695 - 706